Caplin Point Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 16, 2025, 11:17 pm

Market Cap	14,975 Cr.
Current Price	1,972
High / Low	2,641/1,221
Stock P/E	29.1
Book Value	334
Dividend Yield	0.25 %
ROCE	26.5 %
ROE	24.2 %
Face Value	2.00
PEG Ratio	1.80

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Caplin Point Laboratories Ltd

Competitors of Caplin Point Laboratories Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	155 Cr.	110	247/84.3	22.4	36.5	0.00 %	18.0 %	15.5 %	10.0
MPS Pharmaa Ltd	5.77 Cr.	3.02	4.33/2.75		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	45.4 Cr.	61.2	94.9/44.5	15.4	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	35.2 Cr.	24.0	29.0/12.3	35.9	6.64	0.00 %	2.65 %	2.08 %	10.0
Industry Average	17,552.45 Cr	1,110.30		43.07	182.59	0.34%	16.00%	16.30%	6.24

All Competitor Stocks of Caplin Point Laboratories Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	326	339	346	359	372	389	395	410	436	453	459	483	493
Expenses	225	239	244	253	263	265	269	273	293	308	307	318	331
Operating Profit	101	100	102	106	109	124	127	137	142	145	152	165	162
OPM %	31%	29%	30%	29%	29%	32%	32%	34%	33%	32%	33%	34%	33%
Other Income	10	12	14	16	14	11	12	21	17	17	19	21	31
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	12	11	11	11	11	11	11	12	14	16	16	17	16
Profit before tax	99	100	105	110	112	124	127	146	145	146	154	168	177
Tax %	20%	19%	18%	17%	13%	18%	18%	20%	18%	17%	19%	22%	21%
Net Profit	79	81	86	92	97	101	104	116	120	121	125	131	140
EPS in Rs	9.89	10.43	11.21	12.09	12.84	13.45	13.62	15.13	15.43	16.01	16.31	17.21	18.28

Last Updated: March 3, 2025, 5:05 pm

Below is a detailed analysis of the quarterly data for Caplin Point Laboratories Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is 493.00 Cr.. The value appears strong and on an upward trend. It has increased from 483.00 Cr. (Sep 2024) to 493.00 Cr., marking an increase of 10.00 Cr..
For Expenses, as of Dec 2024, the value is 331.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 318.00 Cr. (Sep 2024) to 331.00 Cr., marking an increase of 13.00 Cr..
For Operating Profit, as of Dec 2024, the value is 162.00 Cr.. The value appears to be declining and may need further review. It has decreased from 165.00 Cr. (Sep 2024) to 162.00 Cr., marking a decrease of 3.00 Cr..
For OPM %, as of Dec 2024, the value is 33.00%. The value appears to be declining and may need further review. It has decreased from 34.00% (Sep 2024) to 33.00%, marking a decrease of 1.00%.
For Other Income, as of Dec 2024, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Sep 2024) to 31.00 Cr., marking an increase of 10.00 Cr..
For Interest, as of Dec 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
For Depreciation, as of Dec 2024, the value is 16.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 17.00 Cr. (Sep 2024) to 16.00 Cr., marking a decrease of 1.00 Cr..
For Profit before tax, as of Dec 2024, the value is 177.00 Cr.. The value appears strong and on an upward trend. It has increased from 168.00 Cr. (Sep 2024) to 177.00 Cr., marking an increase of 9.00 Cr..
For Tax %, as of Dec 2024, the value is 21.00%. The value appears to be improving (decreasing) as expected. It has decreased from 22.00% (Sep 2024) to 21.00%, marking a decrease of 1.00%.
For Net Profit, as of Dec 2024, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 131.00 Cr. (Sep 2024) to 140.00 Cr., marking an increase of 9.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 18.28. The value appears strong and on an upward trend. It has increased from 17.21 (Sep 2024) to 18.28, marking an increase of 1.07.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:37 pm

Metric	Jun 2013	Jun 2014	Jun 2015	Mar 2016n n 9m	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	127	173	252	239	402	540	649	863	1,061	1,269	1,467	1,694	1,888
Expenses	105	137	192	175	276	345	417	603	732	874	1,025	1,142	1,264
Operating Profit	22	36	60	64	125	195	232	260	329	395	442	552	624
OPM %	18%	21%	24%	27%	31%	36%	36%	30%	31%	31%	30%	33%	33%
Other Income	2	4	3	4	10	13	19	41	23	38	55	66	88
Interest	1	1	1	0	1	1	1	0	2	1	1	1	1
Depreciation	2	4	8	7	13	19	23	32	37	47	45	53	65
Profit before tax	22	36	53	60	121	188	227	269	314	386	451	564	646
Tax %	37%	27%	23%	24%	21%	23%	22%	20%	20%	20%	16%	18%
Net Profit	14	26	41	46	96	145	177	215	251	308	377	461	517
EPS in Rs	1.85	3.42	5.43	6.05	12.65	19.15	23.35	28.42	32.03	39.56	49.57	60.19	67.81
Dividend Payout %	27%	23%	18%	20%	12%	10%	9%	9%	9%	10%	9%	8%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	51.04%	22.07%	21.47%	16.74%	22.71%	22.40%	22.28%
Change in YoY Net Profit Growth (%)	0.00%	-28.97%	-0.60%	-4.72%	5.96%	-0.31%	-0.12%

Caplin Point Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	30%
5 Years:	21%
3 Years:	17%
TTM:	16%

Compounded Profit Growth
10 Years:	42%
5 Years:	21%
3 Years:	24%
TTM:	18%

Stock Price CAGR
10 Years:	25%
5 Years:	43%
3 Years:	36%
1 Year:	49%

Return on Equity
10 Years:	29%
5 Years:	26%
3 Years:	25%
Last Year:	24%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:33 am

Month	Jun 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	15	15	15	15	15	15	15	15	15	15	15	15	15
Reserves	28	47	78	113	210	349	582	858	954	1,252	1,649	2,084	2,527
Borrowings	5	3	2	2	1	1	36	113	235	219	222	219	2
Other Liabilities	87	115	134	137	133	136	109	139	159	250	305	380	379
Total Liabilities	135	180	229	267	358	500	743	1,126	1,364	1,736	2,191	2,698	2,924
Fixed Assets	33	102	113	144	152	169	227	272	305	287	280	453	465
CWIP	51	25	31	0	3	15	10	20	14	18	221	117	153
Investments	1	0	0	0	17	47	70	61	11	89	281	376	514
Other Assets	50	52	85	122	186	269	436	772	1,033	1,343	1,410	1,753	1,792
Total Assets	135	180	229	267	358	500	743	1,126	1,364	1,736	2,191	2,698	2,924

Below is a detailed analysis of the balance sheet data for Caplin Point Laboratories Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 15.00 Cr..
For Reserves, as of Sep 2024, the value is ₹2,527.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,084.00 Cr. (Mar 2024) to ₹2,527.00 Cr., marking an increase of 443.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹2.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 219.00 Cr. (Mar 2024) to ₹2.00 Cr., marking a decrease of 217.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹379.00 Cr.. The value appears to be improving (decreasing). It has decreased from 380.00 Cr. (Mar 2024) to ₹379.00 Cr., marking a decrease of 1.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹2,924.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,698.00 Cr. (Mar 2024) to ₹2,924.00 Cr., marking an increase of 226.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹465.00 Cr.. The value appears strong and on an upward trend. It has increased from 453.00 Cr. (Mar 2024) to ₹465.00 Cr., marking an increase of 12.00 Cr..
For CWIP, as of Sep 2024, the value is ₹153.00 Cr.. The value appears strong and on an upward trend. It has increased from 117.00 Cr. (Mar 2024) to ₹153.00 Cr., marking an increase of 36.00 Cr..
For Investments, as of Sep 2024, the value is ₹514.00 Cr.. The value appears strong and on an upward trend. It has increased from 376.00 Cr. (Mar 2024) to ₹514.00 Cr., marking an increase of 138.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹1,792.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,753.00 Cr. (Mar 2024) to ₹1,792.00 Cr., marking an increase of 39.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹2,924.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,698.00 Cr. (Mar 2024) to ₹2,924.00 Cr., marking an increase of 226.00 Cr..

Notably, the Reserves (2,527.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Jun 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	32	60	50	42	68	66	83	45	269	337	271	318
Cash from Investing Activity +	-45	-44	-23	-6	-36	-69	-100	-54	-30	-377	-216	-319
Cash from Financing Activity +	-1	-6	-9	-14	-7	-12	90	80	-24	-41	-28	-38
Net Cash Flow	-15	10	19	23	25	-14	73	70	215	-81	27	-39

Free Cash Flow

Month	Jun 2013	Jun 2014	Jun 2015	Mar 2016n n 9m	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	17.00	33.00	58.00	64.00	124.00	194.00	196.00	147.00	94.00	176.00	220.00	333.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Jun 2013	Jun 2014	Jun 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	2	0	8	12	30	85	90	97	96	91	98	117
Inventory Days	45	35	37	57	44	44	47	210	139	149	159	183
Days Payable	111	112	112	168	155	144	76	57	68	102	84	106
Cash Conversion Cycle	-63	-77	-67	-99	-81	-16	61	251	166	138	173	194
Working Capital Days	-176	-181	-128	-114	-29	47	104	167	152	166	146	166
ROCE %	52%	64%	68%	62%	68%	63%	45%	33%	28%	28%	26%	26%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	68.89%	68.88%	68.88%	68.80%	70.66%	70.63%	70.62%	70.62%	70.62%	70.56%	70.56%	70.56%
FIIs	2.07%	2.03%	2.15%	2.24%	2.36%	2.68%	3.09%	2.84%	3.33%	3.38%	3.71%	4.86%
DIIs	1.25%	1.12%	1.12%	1.12%	0.64%	0.27%	0.21%	0.43%	1.08%	1.49%	1.83%	2.11%
Public	27.78%	27.97%	27.85%	27.84%	26.33%	26.44%	26.08%	26.11%	24.95%	24.59%	23.93%	22.48%
No. of Shareholders	83,829	84,868	84,538	82,687	82,146	78,956	78,068	79,438	81,409	80,411	96,123	92,702

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
UTI Aggressive Hybrid Fund	243,164	0.63	38.28	243,164	2025-04-14	0%
UTI Large & Mid Cap Fund	154,097	0.65	24.26	N/A	N/A	N/A
UTI Healthcare Fund	120,000	1.74	18.89	120,000	2025-04-12	0%
UTI Retirement Fund	107,327	0.36	16.89	N/A	N/A	N/A
ITI Pharma and Healthcare Fund	14,758	1.27	2.32	14,758	2025-04-13	0%
Navi Aggressive Hybrid Fund	3,600	0.51	0.57	3,600	2025-04-16	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	60.19	49.62	39.61	32.03	28.42
Diluted EPS (Rs.)	59.90	49.18	39.26	31.71	28.20
Cash EPS (Rs.)	67.79	55.60	46.88	38.13	32.61
Book Value[Excl.RevalReserv]/Share (Rs.)	299.18	241.46	189.35	159.08	116.60
Book Value[Incl.RevalReserv]/Share (Rs.)	299.18	241.46	189.35	159.08	116.60
Revenue From Operations / Share (Rs.)	223.05	193.25	167.47	140.30	114.12
PBDIT / Share (Rs.)	81.42	65.49	57.18	46.56	39.85
PBIT / Share (Rs.)	74.38	59.56	50.99	41.67	35.66
PBT / Share (Rs.)	74.32	59.47	50.90	41.46	35.62
Net Profit / Share (Rs.)	60.75	49.67	40.69	33.24	28.43
NP After MI And SOA / Share (Rs.)	60.18	49.57	39.56	32.03	28.42
PBDIT Margin (%)	36.50	33.88	34.14	33.18	34.91
PBIT Margin (%)	33.34	30.82	30.44	29.70	31.25
PBT Margin (%)	33.31	30.77	30.39	29.55	31.21
Net Profit Margin (%)	27.23	25.70	24.29	23.69	24.91
NP After MI And SOA Margin (%)	26.98	25.65	23.62	22.82	24.90
Return on Networth / Equity (%)	20.39	20.83	21.27	20.43	24.61
Return on Capital Employeed (%)	23.86	23.50	25.28	25.82	27.48
Return On Assets (%)	16.94	17.16	17.26	17.76	19.09
Total Debt / Equity (X)	0.00	0.00	0.00	0.01	0.04
Asset Turnover Ratio (%)	0.69	0.74	0.43	0.48	0.73
Current Ratio (X)	5.71	5.80	6.25	7.25	5.70
Quick Ratio (X)	4.62	4.72	5.15	6.00	4.05
Inventory Turnover Ratio (X)	0.73	0.80	1.41	0.85	3.20
Dividend Payout Ratio (NP) (%)	7.47	8.05	0.00	1.24	0.00
Dividend Payout Ratio (CP) (%)	6.69	7.19	0.00	1.08	0.00
Earning Retention Ratio (%)	92.53	91.95	0.00	98.76	0.00
Cash Earning Retention Ratio (%)	93.31	92.81	0.00	98.92	0.00
Interest Coverage Ratio (X)	792.79	637.23	619.17	221.55	942.76
Interest Coverage Ratio (Post Tax) (X)	592.22	484.22	441.64	159.17	673.77
Enterprise Value (Cr.)	9483.55	4065.67	4717.10	2632.14	1957.49
EV / Net Operating Revenue (X)	5.60	2.77	3.72	2.48	2.27
EV / EBITDA (X)	15.34	8.18	10.88	7.47	6.49
MarketCap / Net Operating Revenue (X)	5.91	3.09	4.06	2.88	2.47
Retention Ratios (%)	92.52	91.94	0.00	98.75	0.00
Price / BV (X)	4.46	2.51	3.66	2.58	2.45
Price / Net Operating Revenue (X)	5.91	3.09	4.06	2.88	2.47
EarningsYield	0.04	0.08	0.05	0.07	0.10

After reviewing the key financial ratios for Caplin Point Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 24, the value is 60.19. This value is within the healthy range. It has increased from 49.62 (Mar 23) to 60.19, marking an increase of 10.57.
For Diluted EPS (Rs.), as of Mar 24, the value is 59.90. This value is within the healthy range. It has increased from 49.18 (Mar 23) to 59.90, marking an increase of 10.72.
For Cash EPS (Rs.), as of Mar 24, the value is 67.79. This value is within the healthy range. It has increased from 55.60 (Mar 23) to 67.79, marking an increase of 12.19.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 299.18. It has increased from 241.46 (Mar 23) to 299.18, marking an increase of 57.72.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 299.18. It has increased from 241.46 (Mar 23) to 299.18, marking an increase of 57.72.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 223.05. It has increased from 193.25 (Mar 23) to 223.05, marking an increase of 29.80.
For PBDIT / Share (Rs.), as of Mar 24, the value is 81.42. This value is within the healthy range. It has increased from 65.49 (Mar 23) to 81.42, marking an increase of 15.93.
For PBIT / Share (Rs.), as of Mar 24, the value is 74.38. This value is within the healthy range. It has increased from 59.56 (Mar 23) to 74.38, marking an increase of 14.82.
For PBT / Share (Rs.), as of Mar 24, the value is 74.32. This value is within the healthy range. It has increased from 59.47 (Mar 23) to 74.32, marking an increase of 14.85.
For Net Profit / Share (Rs.), as of Mar 24, the value is 60.75. This value is within the healthy range. It has increased from 49.67 (Mar 23) to 60.75, marking an increase of 11.08.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 60.18. This value is within the healthy range. It has increased from 49.57 (Mar 23) to 60.18, marking an increase of 10.61.
For PBDIT Margin (%), as of Mar 24, the value is 36.50. This value is within the healthy range. It has increased from 33.88 (Mar 23) to 36.50, marking an increase of 2.62.
For PBIT Margin (%), as of Mar 24, the value is 33.34. This value exceeds the healthy maximum of 20. It has increased from 30.82 (Mar 23) to 33.34, marking an increase of 2.52.
For PBT Margin (%), as of Mar 24, the value is 33.31. This value is within the healthy range. It has increased from 30.77 (Mar 23) to 33.31, marking an increase of 2.54.
For Net Profit Margin (%), as of Mar 24, the value is 27.23. This value exceeds the healthy maximum of 10. It has increased from 25.70 (Mar 23) to 27.23, marking an increase of 1.53.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 26.98. This value exceeds the healthy maximum of 20. It has increased from 25.65 (Mar 23) to 26.98, marking an increase of 1.33.
For Return on Networth / Equity (%), as of Mar 24, the value is 20.39. This value is within the healthy range. It has decreased from 20.83 (Mar 23) to 20.39, marking a decrease of 0.44.
For Return on Capital Employeed (%), as of Mar 24, the value is 23.86. This value is within the healthy range. It has increased from 23.50 (Mar 23) to 23.86, marking an increase of 0.36.
For Return On Assets (%), as of Mar 24, the value is 16.94. This value is within the healthy range. It has decreased from 17.16 (Mar 23) to 16.94, marking a decrease of 0.22.
For Total Debt / Equity (X), as of Mar 24, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.69. It has decreased from 0.74 (Mar 23) to 0.69, marking a decrease of 0.05.
For Current Ratio (X), as of Mar 24, the value is 5.71. This value exceeds the healthy maximum of 3. It has decreased from 5.80 (Mar 23) to 5.71, marking a decrease of 0.09.
For Quick Ratio (X), as of Mar 24, the value is 4.62. This value exceeds the healthy maximum of 2. It has decreased from 4.72 (Mar 23) to 4.62, marking a decrease of 0.10.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.73. This value is below the healthy minimum of 4. It has decreased from 0.80 (Mar 23) to 0.73, marking a decrease of 0.07.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 7.47. This value is below the healthy minimum of 20. It has decreased from 8.05 (Mar 23) to 7.47, marking a decrease of 0.58.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 6.69. This value is below the healthy minimum of 20. It has decreased from 7.19 (Mar 23) to 6.69, marking a decrease of 0.50.
For Earning Retention Ratio (%), as of Mar 24, the value is 92.53. This value exceeds the healthy maximum of 70. It has increased from 91.95 (Mar 23) to 92.53, marking an increase of 0.58.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 93.31. This value exceeds the healthy maximum of 70. It has increased from 92.81 (Mar 23) to 93.31, marking an increase of 0.50.
For Interest Coverage Ratio (X), as of Mar 24, the value is 792.79. This value is within the healthy range. It has increased from 637.23 (Mar 23) to 792.79, marking an increase of 155.56.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 592.22. This value is within the healthy range. It has increased from 484.22 (Mar 23) to 592.22, marking an increase of 108.00.
For Enterprise Value (Cr.), as of Mar 24, the value is 9,483.55. It has increased from 4,065.67 (Mar 23) to 9,483.55, marking an increase of 5,417.88.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 5.60. This value exceeds the healthy maximum of 3. It has increased from 2.77 (Mar 23) to 5.60, marking an increase of 2.83.
For EV / EBITDA (X), as of Mar 24, the value is 15.34. This value exceeds the healthy maximum of 15. It has increased from 8.18 (Mar 23) to 15.34, marking an increase of 7.16.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.91. This value exceeds the healthy maximum of 3. It has increased from 3.09 (Mar 23) to 5.91, marking an increase of 2.82.
For Retention Ratios (%), as of Mar 24, the value is 92.52. This value exceeds the healthy maximum of 70. It has increased from 91.94 (Mar 23) to 92.52, marking an increase of 0.58.
For Price / BV (X), as of Mar 24, the value is 4.46. This value exceeds the healthy maximum of 3. It has increased from 2.51 (Mar 23) to 4.46, marking an increase of 1.95.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.91. This value exceeds the healthy maximum of 3. It has increased from 3.09 (Mar 23) to 5.91, marking an increase of 2.82.
For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.08 (Mar 23) to 0.04, marking a decrease of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Caplin Point Laboratories Ltd as of April 17, 2025 is: 1,886.38

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of April 17, 2025, Caplin Point Laboratories Ltd is Overvalued by 4.34% compared to the current share price 1,972.00

Intrinsic Value of Caplin Point Laboratories Ltd as of April 17, 2025 is: 2,191.68

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of April 17, 2025, Caplin Point Laboratories Ltd is Undervalued by 11.14% compared to the current share price 1,972.00

Last 5 Year EPS CAGR: 16.18%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 46.92%, which is a positive sign. The stock has a low average Working Capital Days of 26.67, which is a positive sign. The company has higher reserves (825.46 cr) compared to borrowings (81.54 cr), indicating strong financial stability. The company has shown consistent growth in sales (250.00 cr) and profit (256.69 cr) over the years.	The stock has a high average Cash Conversion Cycle of 48.33, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Caplin Point Laboratories Ltd:
1. Net Profit Margin: 27.23%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 23.86% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 20.39% (Industry Average ROE: 16.3%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 592.22
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 4.62
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 29.1 (Industry average Stock P/E: 43.07)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Caplin Point Laboratories Ltd. is a Public Limited Listed company incorporated on 16/04/1990 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24231TN1990PLC019053 and registration number is 019053. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 625.09 Cr. and Equity Capital is Rs. 15.19 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	3rd Floor, Ashvich Towers, No.3, Developed Plots Industrial Chennai (Madras) Tamil Nadu 600096	info@caplinpoint.net www.caplinpoint.net

Management
Name	Position Held
Mr. C C Paarthipan	Chairman
Dr. Sridhar Ganesan	Managing Director
Dr. R Nagendran	Independent Director
Mr. S Deenadayalan	Independent Director
Mr. D Sathyanarayanan	Independent Director
Dr. C K Gariyali	Independent Director

FAQ

What is the intrinsic value of Caplin Point Laboratories Ltd?

Caplin Point Laboratories Ltd's intrinsic value (as of 17 April 2025) is ₹1886.38 — 4.34% lower the current market price of 1,972.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 14,975 Cr. market cap, FY2025-2026 high/low of ₹2,641/1,221, reserves of 2,527 Cr, and liabilities of 2,924 Cr.

What is the Market Cap of Caplin Point Laboratories Ltd?

The Market Cap of Caplin Point Laboratories Ltd is 14,975 Cr..

What is the current Stock Price of Caplin Point Laboratories Ltd as on 17 April 2025?

The current stock price of Caplin Point Laboratories Ltd as on 17 April 2025 is 1,972.

What is the High / Low of Caplin Point Laboratories Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Caplin Point Laboratories Ltd stocks is ₹2,641/1,221.

What is the Stock P/E of Caplin Point Laboratories Ltd?

The Stock P/E of Caplin Point Laboratories Ltd is 29.1.

What is the Book Value of Caplin Point Laboratories Ltd?

The Book Value of Caplin Point Laboratories Ltd is 334.

What is the Dividend Yield of Caplin Point Laboratories Ltd?

The Dividend Yield of Caplin Point Laboratories Ltd is 0.25 %.

What is the ROCE of Caplin Point Laboratories Ltd?

The ROCE of Caplin Point Laboratories Ltd is 26.5 %.

What is the ROE of Caplin Point Laboratories Ltd?

The ROE of Caplin Point Laboratories Ltd is 24.2 %.

What is the Face Value of Caplin Point Laboratories Ltd?

The Face Value of Caplin Point Laboratories Ltd is 2.00.